EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma

Lisa Marie Fröhlich, Ana Villar-Miyar, Tamara Heintze, Birgit Sauer, Birgit Schittek iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Lisa Marie Fröhlich und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Melanoma, Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerase Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG), Germany's Excellence Strategy, Wilhelm Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic melanoma is still a difficult‐to‐treat cancer type owing to its frequent resistance mechanisms to targeted and immunotherapy. Therefore, we aimed to unravel novel therapeutic strategies for melanoma patients. Preclinical and clinical studies show that melanoma patients may benefit from a treatment with poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi). In this study, we focus on PARP1 as a potential biomarker to predict the response of melanoma cells to PARPi therapy. We found that melanoma cells with high basal PARP1 expression exhibit significantly increased cell death after PARPi treatment owing to higher PARP1 trapping compared with melanoma cells with low PARP1 expression. In addition, we could demonstrate that PARP1 expression levels are low in nonmalignant skin cells, and metastatic melanomas show considerably higher PARP1 levels compared with primary melanomas. Most strikingly, we found that high PARP1 levels correlate with worse overall survival of late stage metastasized melanoma patients. In conclusion, we show that PARP1 might act as a biomarker to predict the response to PARPi therapy, and that in particular the late stage metastasized melanoma patients are especially sensitive to PARPi therapy owing to elevated PARP1 expression. Our data suggest that the PARPi cytotoxicity primarily will affect the high PARP1 expressing melanoma cells, rather than the low PARP1 expressing nonmalignant skin cells resulting in only low side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsSkin NeoplasmsFemaleHumansMaleBiomarkers, TumorCell Line, TumorDrug Resistance, NeoplasmNeoplasm MetastasisPoly(ADP-ribose) PolymerasesPrognosis

Stichwörter der Autor:innen

PARP inhibitorsPARP1biomarkermelanoma

Substanzen

Biomarkers, TumorPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Dermatology, Division of Dermatooncology, University of Tübingen, Tübingen, Germany.
  • Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.

ORCID-Profile: Birgit Schittek

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)
  • Germany's Excellence Strategy
  • Wilhelm Sander-Stiftung

Zitieren

APA

Fröhlich, L. M., Villar-Miyar, A., Heintze, T., Sauer, B., & Schittek, B. (2024). PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. International Journal of Cancer. https://doi.org/10.1002/ijc.34947

Vancouver

Fröhlich LM, Villar-Miyar A, Heintze T, Sauer B, Schittek B. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma. International Journal of Cancer. 2024. doi:10.1002/ijc.34947

BibTeX
@article{Frhlich2024,
  author = {Fröhlich, Lisa Marie and Villar-Miyar, Ana and Heintze, Tamara and Sauer, Birgit and Schittek, Birgit},
  title = {PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34947}
}
Kostenlos starten →